Anger as SMC rejects enzalutamide
Press Releases • Aug 10, 2015 00:01 BST
Prostate Cancer UK has expressed anger at the Scottish Medicines Consortium’s (SMC) decision to reject the life-prolonging and life-enhancing drug, enzalutamide, for use on NHS Scotland for men with incurable advanced prostate cancer who have not received chemotherapy.